Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

about

Treating pediatric neuromuscular disorders: The future is now.Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes.

P2860

Q52756417-7FB95AE0-D055-4EA1-9901-8218F95A58E0 Q55417954-E873D281-5730-4193-A9E7-A0923A78D2BC

P2860

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

Item

http://www.wikidata.org/entity/Q40632053

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

@en

type

Item

label

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

@en

prefLabel

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

@en

P1476

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

@en

P2093

Carlos A Báez-Pagán

http://www.w3.org/2001/XMLSchema#string

Christopher M Gomez

http://www.w3.org/2001/XMLSchema#string

Gary E Grajales-Reyes

http://www.w3.org/2001/XMLSchema#string

Haipeng Zhu

http://www.w3.org/2001/XMLSchema#string

Jose A Lasalde-Dominicci

http://www.w3.org/2001/XMLSchema#string

Jose G Grajales-Reyes

http://www.w3.org/2001/XMLSchema#string

KaReisha Robinson

http://www.w3.org/2001/XMLSchema#string

Peter Pytel

http://www.w3.org/2001/XMLSchema#string

Vivianette Alicea-Vázquez

http://www.w3.org/2001/XMLSchema#string

P2860

A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome

Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139

Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms

Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome

Agonist-induced myopathy at the neuromuscular junction is mediated by calcium.

Pharmacokinetics of second generation antidepressants: fluoxetine.

Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals.

Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions.

Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals.

P304

88-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPNEUROL.2014.10.008

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

270

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25448156

http://www.w3.org/2001/XMLSchema#string

P921

fluoxetine

birth defect

P932

4430442

http://www.w3.org/2001/XMLSchema#string

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

about

P2860

P2860

Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932